Linker Information

General Information of This Linker

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

ADC3-1 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	66.40%	Positive HER2 expression (HER2 +++/++)
Method Description	Seeding cells (HCC1569) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78.60%	High HER2 expression (HER2+++)
Method Description	The in vitro potency of ADC was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	High HER2 expression (HER2+++)
Method Description	The in vitro potency of ADC was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.15 nM	Positive HER2 expression (HER2 +++/++)
Method Description	Seeding cells (HCC1569) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

References

Ref 1	Antibody drug conjugates; 2023-07-06.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.